New data reveals £389 displaced from households’ grocery spend each year as weight loss drugs used in nearly one in ten UK homes 

GLP-1 usage is expected to continue to rise in 2027, according to Worldpanel

GLP-1 usage is expected to continue to rise in 2027, according to Worldpanel

Image: Adobe Stock

UK households with a GLP-1 user collectively spent £1bn less on groceries than expected, compared with similar households, according to new data from Worldpanel by Numerator released today, up from £780mn in June.

The data shows that 415mn fewer packs have been purchased, equating to an average £389 a year being displaced from the shopping baskets of households using the drugs, it added. 

While spend and volume at UK supermarkets are declining at a similar rate overall, products typically associated with impulse purchases and indulgence, including alcohol and crisps, are bearing the brunt of the impact. 

By contrast, convenient, portion-controlled options are gaining ground. Frozen ready meals, for example, have recorded a 30 per cent uplift in volume, highlighting the continued appeal of smaller, easy-to-digest everyday comforts. 

Chantel Kennaugh, head of public sector and nutrition at Worldpanel, said: “From a grocery perspective, this new audience is being more mindful about what and how they eat. The key for retailers is how to support them, without isolating them. 

“This might be as simple as producing clear labels that highlight nutrients like high protein or ensuring ranges are available in smaller portions sizes.”

The findings come as the number of British households with a GLP-1 user has risen from 6.3 per cent in February to 8.5 per cent in August, representing 2.6mn adults. 

GLP-1 users are now present in as many British households as vegetarians and pescatarians combined, a similar proportion to the number of households buying Corona beer (8.4 per cent) or Kellogg’s Rice Krispies (8.6 per cent).

Nishita Pattni, senior consultant, said: “In just six months, between February and August 2026, user numbers rose almost as much as they did in the whole of the previous year.”

Despite only receiving approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in June 2026, pills now account for 11.2 per cent of GLP-1 users, with male users driving much of the growth. Male users make up 32 per cent of users, up from 23 per cent in February, nearly doubling. 

“For many people, a daily pill is far easier than an injection, and with the surge in male users, we only expect the appeal of these drugs to grow,” Pattni added.

Worldpanel forecasts that GLP-1 usage will surpass 10 per cent of UK households in 2027. Kennaugh said this would bring about a “seismic change”, requiring retailers and manufacturers to re-think their strategies.